Suppr超能文献

人群层面胰腺腺癌辅助治疗的预测因素。

Predictors of adjuvant treatment for pancreatic adenocarcinoma at the population level.

作者信息

Kagedan D J, Dixon M E, Raju R S, Li Q, Elmi M, Shin E, Liu N, El-Sedfy A, Paszat L, Kiss A, Earle C C, Mittmann N, Coburn N G

机构信息

Division of General Surgery, Department of Surgery, University of Toronto, Toronto, ON.

Department of Surgery, Maimonides Medical Center, Brooklyn, NY, U.S.A.

出版信息

Curr Oncol. 2016 Oct;23(5):334-342. doi: 10.3747/co.23.3205. Epub 2016 Oct 25.

Abstract

BACKGROUND

In the present study, we aimed to describe, at the population level, patterns of adjuvant treatment use after curative-intent resection for pancreatic adenocarcinoma (pcc) and to identify independent predictors of adjuvant treatment use.

METHODS

In this observational cohort study, patients undergoing pcc resection in the province of Ontario (population 13 million) during 2005-2010 were identified using the provincial cancer registry and were linked to administrative databases that include all treatments received and outcomes experienced in the province. Patients were defined as having received chemotherapy (ctx), chemoradiation (crt), or observation (obs). Clinicopathologic factors associated with the use of ctx, crt, or obs were identified by chi-square test. Logistic regression analyses were used to identify independent predictors of adjuvant treatment versus obs, and ctx versus crt.

RESULTS

Of the 397 patients included, 75.3% received adjuvant treatment (27.2% crt, 48.1% ctx) and 24.7% received obs. Within a single-payer health care system with universal coverage of costs for ctx and crt, substantial variation by geographic region was observed. Although the likelihood of receiving adjuvant treatment increased from 2005 to 2010 ( = 0.002), multivariate analysis revealed widespread variation between the treating hospitals ( = 0.001), and even between high-volume hepatopancreatobiliary hospitals ( = 0.0006). Younger age, positive lymph nodes, and positive surgical resection margins predicted an increased likelihood of receiving adjuvant treatment. Among patients receiving adjuvant treatment, positive margins and a low comorbidity burden were associated with crt compared with ctx.

CONCLUSIONS

Interinstitutional medical practice variation contributes significantly to differential patterns in the rate of adjuvant treatment for pcc. Whether such variation is warranted or unwarranted requires further investigation.

摘要

背景

在本研究中,我们旨在描述在人群水平上,胰腺癌(PCC)根治性切除术后辅助治疗的使用模式,并确定辅助治疗使用的独立预测因素。

方法

在这项观察性队列研究中,利用省级癌症登记处确定了2005年至2010年期间在安大略省(人口1300万)接受PCC切除的患者,并将其与行政数据库相链接,该数据库包含该省接受的所有治疗和经历的结局。患者被定义为接受了化疗(CTX)、放化疗(CRT)或观察(OBS)。通过卡方检验确定与使用CTX、CRT或OBS相关的临床病理因素。采用逻辑回归分析确定辅助治疗与观察、CTX与CRT的独立预测因素。

结果

在纳入的397例患者中,75.3%接受了辅助治疗(27.2%为CRT,48.1%为CTX),24.7%接受了观察。在单一支付者医疗保健系统中,CTX和CRT费用普遍覆盖,观察到地理区域存在显著差异。尽管从2005年到2010年接受辅助治疗的可能性增加(P = 0.002),但多变量分析显示治疗医院之间存在广泛差异(P = 0.001),甚至在高容量肝胰胆医院之间也存在差异(P = 0.0006)。年龄较小、淋巴结阳性和手术切缘阳性预示接受辅助治疗的可能性增加。在接受辅助治疗的患者中,与CTX相比,切缘阳性和低合并症负担与CRT相关。

结论

机构间医疗实践差异对PCC辅助治疗率的差异模式有显著影响。这种差异是否合理需要进一步研究。

相似文献

1
Predictors of adjuvant treatment for pancreatic adenocarcinoma at the population level.
Curr Oncol. 2016 Oct;23(5):334-342. doi: 10.3747/co.23.3205. Epub 2016 Oct 25.
4
Multi-institutional pooled analysis on adjuvant chemoradiation in pancreatic cancer.
Int J Radiat Oncol Biol Phys. 2014 Nov 15;90(4):911-7. doi: 10.1016/j.ijrobp.2014.07.024. Epub 2014 Sep 11.
5
Evaluation of preoperative therapy for pancreatic cancer using a prognostic nomogram.
Ann Surg Oncol. 2006 Nov;13(11):1485-92. doi: 10.1245/s10434-006-9104-y. Epub 2006 Sep 30.
7
Impact of external-beam radiation therapy on outcomes among patients with resected gastric cancer: a multi-institutional analysis.
Ann Surg Oncol. 2014 Oct;21(11):3412-21. doi: 10.1245/s10434-014-3776-5. Epub 2014 May 21.
9
Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer?
J Surg Oncol. 2012 Jul 1;106(1):111-8. doi: 10.1002/jso.23044. Epub 2012 Feb 6.

本文引用的文献

1
Describing Patterns of Care in Pancreatic Cancer: A Population-Based Study.
Pancreas. 2015 Nov;44(8):1259-65. doi: 10.1097/MPA.0000000000000384.
2
Methodological issues in observational studies and non-randomized controlled trials in oncology in the era of big data.
Jpn J Clin Oncol. 2015 Apr;45(4):323-7. doi: 10.1093/jjco/hyu220. Epub 2015 Jan 14.
3
Prognostic factors in metastatic gastric cancer: results of a population-based, retrospective cohort study in Ontario.
Gastric Cancer. 2016 Jan;19(1):150-9. doi: 10.1007/s10120-014-0442-3. Epub 2014 Nov 25.
4
Improved long-term outcomes after resection of pancreatic adenocarcinoma: a comparison between two time periods.
Ann Surg Oncol. 2015 Apr;22(4):1160-7. doi: 10.1245/s10434-014-4196-2. Epub 2014 Oct 28.
6
Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer.
Ann Surg. 2014 Aug;260(2):372-7. doi: 10.1097/SLA.0000000000000378.
8
Adjuvant treatments for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis.
Lancet Oncol. 2013 Oct;14(11):1095-1103. doi: 10.1016/S1470-2045(13)70388-7. Epub 2013 Sep 12.
9
Impact of adjuvant radiotherapy on survival after pancreatic cancer resection: an appraisal of data from the national cancer data base.
Ann Surg Oncol. 2013 Oct;20(11):3634-42. doi: 10.1245/s10434-013-3047-x. Epub 2013 Jun 15.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验